Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Guselkumab - Janssen Biotech

Next Previous
Drug Profile

Guselkumab - Janssen Biotech

Alternative Names: CNTO-1959; TREMFYA; TREMFYA ONE-PRESS; Tremphia

Latest Information Update: 03 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MorphoSys
  • Developer Janssen Biotech; Janssen Pharmaceutical KK; Janssen Research & Development; Janssen-Cilag; MorphoSys; Taiho Pharmaceutical
  • Class Anti-inflammatories; Antineoplastics; Antipsoriatics; Antirheumatics; Monoclonal antibodies; Skin disorder therapies; Urologics
  • Mechanism of Action Interleukin-23 subunit p19 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Crohn's disease; Erythrodermic psoriasis; Juvenile rheumatoid arthritis; Palmoplantar pustulosis; Plaque psoriasis; Psoriasis; Psoriatic arthritis; Pustular psoriasis; Ulcerative colitis
  • Phase II Hidradenitis suppurativa; Systemic scleroderma
  • Discontinued Familial adenomatous polyposis; Giant cell arteritis; Lupus nephritis; Rheumatoid arthritis

Most Recent Events

  • 30 Mar 2026 Janssen Research & Development, LLC plans a phase III CHARGE trial for Chrohn's disease (SC) in April 2026 (NCT07499232)
  • 21 Feb 2026 Long-term efficacy data from a phase-IIb/III QUASAR trial in Ulcerative colitis released by Johnson & Johnson
  • 19 Dec 2025 Registered for Plaque psoriasis (In adolescents, In children) in European Union (SC)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top